Coherus BioSciences Files 8-K on Material Agreement, Lacks Details

TL;DR

**Coherus filed an 8-K for a material agreement, but it's a placeholder with no actual info yet.**

AI Summary

Coherus BioSciences, Inc. filed an 8-K on February 5, 2024, to report an "Entry into a Material Definitive Agreement" and "Regulation FD Disclosure." While the filing indicates a significant event, it does not provide specific details about the agreement or disclosure, such as names or dollar amounts. This matters to investors because without the specifics, it's impossible to assess the financial impact or strategic implications of this material event on Coherus BioSciences' stock.

Why It Matters

This filing signals a potentially significant business development for Coherus BioSciences, but the lack of specific details prevents investors from understanding its financial implications or strategic importance.

Risk Assessment

Risk Level: medium — The filing indicates a material event without providing any details, creating uncertainty and making it impossible to assess the actual impact, which is a medium risk.

Analyst Insight

A smart investor would monitor subsequent filings from Coherus BioSciences, Inc. for detailed information regarding the 'Material Definitive Agreement' and 'Regulation FD Disclosure' to assess their financial and strategic impact before making any investment decisions.

Key Players & Entities

• Coherus BioSciences, Inc. (company) — the registrant filing the 8-K
• February 5, 2024 (date) — date of earliest event reported and filing date

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share CHRS The Nasdaq
• $175,000,000 — xisting Loan Agreement in the amount of $175,000,000 upon consummation of the transactions c

Filing Documents

• chrs-20240205x8k.htm (8-K) — 45KB
• chrs-20240205xex10d1.htm (EX-10.1) — 105KB
• chrs-20240205xex99d1.htm (EX-99.1) — 15KB
• chrs-20240205xex99d1001.jpg (GRAPHIC) — 7KB
• 0001558370-24-000740.txt ( ) — 317KB
• chrs-20240205.xsd (EX-101.SCH) — 4KB
• chrs-20240205_def.xml (EX-101.DEF) — 3KB
• chrs-20240205_lab.xml (EX-101.LAB) — 16KB
• chrs-20240205_pre.xml (EX-101.PRE) — 10KB
• chrs-20240205x8k_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On February 5, 2024, Coherus BioSciences, Inc. (the "Company"), as borrower and on behalf of itself and certain of its subsidiaries, entered into a Consent, Partial Release and Third Amendment to Loan Agreement (the "Consent and Amendment") with Biopharma Credit PLC, a public limited company incorporated under the laws of England and Wales, as collateral agent (the "Collateral Agent"), BPCR Limited Partnership, a limited partnership established under the laws of England and Wales, as a lender ("BPCR"), and Biopharma Credit Investments V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a lender, and together with as BPCR, each, a "Lender" and collectively, the "Lenders"), pursuant to which the Lenders and the Collateral Agent provided certain consents, and released certain assets and subsidiaries of the Company from their obligations under the Existing Loan Agreement and the other loan documents in connection therewith, and the parties thereto agreed to amend the previously disclosed loan agreement dated as of January 5, 2022 (as amended on April 7, 2022 and February 6, 2023, and as further amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date of the Consent and Amendment, the "Existing Loan Agreement") among the Company, certain of its subsidiaries, the Collateral Agent and the Lenders. Pursuant to and subject to terms and conditions in the Consent and Amendment, among other things: (1) the Lenders and the Collateral Agent provided consent to consummation of the transactions contemplated by that certain Purchase and Sale Agreement dated as of January 19, 2024 (the "Purchase Agreement") by and between the Company and Sandoz Inc., a Delaware corporation, and released certain subsidiary of the Company from its obligation and certain assets subject to the transactions contem

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On February 5, 2024, the Company announced that it had entered into the Consent and Amendment. A copy of the press release is attached to this Current Report as Exhibit 99.1 and incorporated herein by reference. The information in Item 7.01 of this Current Report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for purposes of Section 18 of Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act").

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Consent, Partial Release and Third Amendment to Loan Agreement dated as of February 5, 2024 among Coherus BioSciences, Inc., Biopharma Credit PLC, BPCR Limited Partnership and Biopharma Credit Investments V (MASTER) LP * 99.1 Press Release of Coherus BioSciences, Inc., dated February 5, 2024 104 Cover page Interactive Data file (embedded within the Inline XBRL document) * Certain portions of this document that constitute confidential information have been redacted in accordance with Regulation S-K, Item 601(b)(10).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 5, 2024 COHERUS BIOSCIENCES, INC. By: /s/ Dennis M. Lanfear Name: Dennis M. Lanfear Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR